{
    "ticker": "PBYI",
    "name": "Puma Biotechnology, Inc.",
    "description": "Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of various forms of cancer. Founded in 2010 and headquartered in Los Angeles, California, Puma's mission is to enhance the lives of cancer patients through the delivery of important pharmaceutical products. The company\u2019s lead product, NERLYNX (neratinib), is an oral therapy designed to improve outcomes in patients with HER2-positive breast cancer, particularly those who have previously been treated with trastuzumab-based therapies. Puma Biotechnology is committed to advancing its pipeline of drug candidates aimed at addressing unmet medical needs in oncology. The company actively collaborates with academic institutions and research organizations to explore potential new treatments, ensuring it remains at the forefront of cancer research and development. With a strong focus on patient-centric approaches, Puma is dedicated to providing valuable support and resources for patients and healthcare professionals alike.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2010",
    "website": "https://www.pumabiotechnology.com",
    "ceo": "Alan H. Auerbach",
    "social_media": {
        "twitter": "https://twitter.com/PumaBiotech",
        "linkedin": "https://www.linkedin.com/company/puma-biotechnology/"
    },
    "investor_relations": "https://investors.pumabiotechnology.com",
    "key_executives": [
        {
            "name": "Alan H. Auerbach",
            "position": "CEO"
        },
        {
            "name": "Lynne A. H. K. M. D. McGhee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Treatments",
            "products": [
                "NERLYNX (neratinib)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Puma Biotechnology, Inc. | Innovating Cancer Treatments",
        "meta_description": "Puma Biotechnology, Inc. is dedicated to developing innovative cancer therapies. Explore Puma's pioneering oncology products and their impact on patient care.",
        "keywords": [
            "Puma Biotechnology",
            "Cancer Treatment",
            "NERLYNX",
            "HER2-positive Breast Cancer",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Puma Biotechnology specialize in?",
            "answer": "Puma Biotechnology specializes in developing and commercializing innovative cancer treatments."
        },
        {
            "question": "What is NERLYNX?",
            "answer": "NERLYNX is an oral therapy developed by Puma for the treatment of HER2-positive breast cancer."
        },
        {
            "question": "When was Puma Biotechnology founded?",
            "answer": "Puma Biotechnology was founded in 2010."
        },
        {
            "question": "Where is Puma Biotechnology headquartered?",
            "answer": "Puma Biotechnology is headquartered in Los Angeles, California, USA."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "MRK",
        "ROG"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "ABBV",
        "REGN"
    ]
}